{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:21:34Z","timestamp":1762521694165},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.gastrohep.2014.04.003","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T19:23:22Z","timestamp":1402946602000},"page":"78-81","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["La interrupci\u00f3n precoz del tratamiento triple con telaprevir de la hepatitis cr\u00f3nica C por efecto adverso grave no presupone necesariamente el fracaso del tratamiento"],"prefix":"10.1016","volume":"38","author":[{"given":"Silvia","family":"Virol\u00e9s Torrent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"L\u00f3pez Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoli","family":"Hombrados Verde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Figa Francesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Ferri Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Louvriex Freire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doroteo","family":"Acero Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2014.04.003_bib0005","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir and perginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchinson","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2014.04.003_bib0010","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2014.04.003_bib0015","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchinson","year":"2010","journal-title":"N Eng J Med."},{"key":"10.1016\/j.gastrohep.2014.04.003_bib0020","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Eng J Med."},{"key":"10.1016\/j.gastrohep.2014.04.003_bib0025","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Eng J Med."},{"key":"10.1016\/j.gastrohep.2014.04.003_bib0030","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Eng J Med."},{"key":"10.1016\/j.gastrohep.2014.04.003_bib0035","unstructured":"Nelson DR, Poordad F, Feld JJ, Fried MM, Jacobson IM, Pockros PJ, et al. and the CONCISE study team. Efficacy and tolerability of a 12-week telaprevir regime in treatment-naive and prior relapser patients with genotype 1 HCV infection and IL28B CC genotype: Results of the CONCISE study. Global Antiviral J. 9; Suppl 2; S99-S100."},{"key":"10.1016\/j.gastrohep.2014.04.003_bib0040","first-page":"374A","article-title":"Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon\/Ribavirina treatment failure: Subanalysis of the REALIZE phase II study","volume":"54","author":"Pol","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2014.04.003_bib0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jhep.2012.12.023","article-title":"Limited impact of IL28B genotype on response rates in telaprevir-tretaed patients with prior treatment failure","volume":"58","author":"Pol","year":"2013","journal-title":"J Hepatol."},{"key":"10.1016\/j.gastrohep.2014.04.003_bib0050","first-page":"375A","article-title":"Predictors of virologic response with telaprevir-based combination tretament in HCV genotype 1-infected patients with prior peg-inf\/ribavirin failure: Post-hoc analysis of the phase III REALIZE study","volume":"54","author":"Berg","year":"2011","journal-title":"Hepatology."}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057051400140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057051400140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T05:55:15Z","timestamp":1538546115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021057051400140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S021057051400140X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2014.04.003","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La interrupci\u00f3n precoz del tratamiento triple con telaprevir de la hepatitis cr\u00f3nica C por efecto adverso grave no presupone necesariamente el fracaso del tratamiento","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2014.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}